Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07599813 · ClinicalTrials.gov registry record · Phase 2
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
A Phase 2 study, sponsored by Apollo Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 280
- Enrollment target
NCT07599813 is a Phase 2 study that is actively recruiting participants, run by Apollo Therapeutics. The registered enrollment target is 280 participants.
The verdict
NCT07599813, a Phase 2 study, is actively recruiting participants, sponsored by Apollo Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 280 participants
- Enrollment target
Study Summary
This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.
Interventions
- DRUG Placebo
- DRUG Camoteskimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2026-05-28 |
| Est. Completion | 2028-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07599813
The ClinicalTrials.gov registry entry for NCT07599813 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 280 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Apollo Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07599813 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07599813 about?
NCT07599813 is a clinical study titled "A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis". This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.
What is the current status of trial NCT07599813?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 280 participants. The study started on 2026-05-28. Estimated completion is 2028-04-30.
What interventions are being tested in trial NCT07599813?
The interventions under investigation include: Placebo (DRUG), Camoteskimab (DRUG).
Who is sponsoring clinical trial NCT07599813?
This trial is sponsored by Apollo Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.